financetom
Business
financetom
/
Business
/
Red’s Home & Garden Joins SiteOne Landscape Supply
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Red’s Home & Garden Joins SiteOne Landscape Supply
Oct 8, 2025 6:18 AM

ROSWELL, Ga.--(BUSINESS WIRE)--

SiteOne® Landscape Supply, Inc. announced today its acquisition of Red’s Home & Garden, a wholesale distributor of nursery and hardscapes products with one location in Wilkesboro, North Carolina, about 35 miles east of Boone.

“This acquisition provides a strategic entry into North Carolina’s Appalachian market and establishes a footprint to expand all our product lines to better serve our combined customers,” said Doug Black, Chairman and CEO of SiteOne. “We’re excited to welcome the talented team and valued customers of Red’s Home & Garden to the SiteOne family.”

“SiteOne has a proven track record of success and a commitment to excellence,” said Daniel Furches, co-owner and general manager of Red’s Home and Garden. “I’m confident that joining the SiteOne family will create new opportunities for our employees and ensure that our customers continue to receive the highest level of service and support for years to come.”

This is the sixth acquisition in 2025 for SiteOne as the company continues to expand the number of markets in which it offers a full range of landscape supplies and services to landscape professionals.

About SiteOne Landscape Supply ( SITE ):

SiteOne Landscape Supply, Inc. ( SITE ) , is the largest and only full product line national wholesale distributor of landscape supplies in the United States and has an established presence in Canada. Its customers are primarily residential and commercial landscape professionals who specialize in the design, installation and maintenance of lawns, gardens, golf courses and other outdoor spaces. https://www.siteone.com/

Source: SiteOne Landscape Supply, Inc. ( SITE )

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Alphabet Insider Sold Shares Worth $1,962,700, According to a Recent SEC Filing
Alphabet Insider Sold Shares Worth $1,962,700, According to a Recent SEC Filing
Mar 27, 2025
05:48 PM EDT, 03/27/2025 (MT Newswires) -- John Kent Walker, President, Global Affairs, Chief Legal Officer, on March 25, 2025, sold 11,764 shares in Alphabet (GOOGL) for $1,962,700. Following the Form 4 filing with the SEC, Walker has control over a total of 49,037 Class C capital shares of the company, with 49,037 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1652044/000095017025046216/xslF345X05/ownership.xml ...
Liberty CEO Gusek sees modest impact of steel tariffs on oilfield services
Liberty CEO Gusek sees modest impact of steel tariffs on oilfield services
Mar 27, 2025
NEW YORK (Reuters) - Oilfield service providers will face modest hits to earnings from U.S. President Donald Trump's decision to impose tariffs on steel imports, Liberty Energy Chief Executive Ron Gusek said on Thursday. Trump imposed 25% tariffs on steel and aluminum on March 12, and more could be coming April 2. A Dallas Federal Reserve survey on Wednesday showed...
GameStop Prices $1.3 Billion Private Offering of Notes
GameStop Prices $1.3 Billion Private Offering of Notes
Mar 27, 2025
05:49 PM EDT, 03/27/2025 (MT Newswires) -- GameStop ( GME ) said Thursday that it priced a $1.3 billion private offering of 0% convertible senior notes due 2030. Initial purchasers of the notes have a 13-day option to buy up to an additional $200 million of notes, according to the company. GameStop ( GME ) expects to close the offering...
Spyre Therapeutics Starts Dosing in Phase 1 Trial for IL-23 Antibody SPY003
Spyre Therapeutics Starts Dosing in Phase 1 Trial for IL-23 Antibody SPY003
Mar 27, 2025
05:49 PM EDT, 03/27/2025 (MT Newswires) -- Spyre Therapeutics ( SYRE ) said Thursday it has begun dosing in a phase 1 trial for SPY003, its investigational extended half-life anti-IL-23 monoclonal antibody, in healthy volunteers. The phase 1 trial is a double-blind, placebo-controlled, single-ascending dose study enrolling about 56 healthy adult participants. The study's primary endpoint is safety, with pharmacokinetics...
Copyright 2023-2026 - www.financetom.com All Rights Reserved